She credited the same risk assessment test that led to her own diagnosis in 2023 with potentially saving her mother's life.

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival ...

In one of the first large-scale analyses of antibody-drug conjugates (ADCs) by race, a study presented at the recent American Society of Clinical Oncology (ASCO) meeting found that Black patients with ...

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

A new study shows that racial and ethnic disparities among Medicare beneficiaries who receive ERBB2 (formerly HER2)-targeted therapies for breast cancer have narrowed significantly from 2010 to ...

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Stage 0 breast cancer: Cancer has not spread from the ducts (Tis ... Targeted therapy drugs seek out specific proteins and ...

Olivia Munn has for more than a year been speaking out about the importance of a breast cancer risk assessment test that helped lead to her diagnosis in ...